Showing results (61-70 of 80) with videos related to
Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2011
Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumorsAdil I Daud, Smitha S Krishnamurthi, Mansoor N Saleh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced MelanomaCaroline Robert, Matteo S Carlino, Catriona McNeil, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumorsAdil I Daud, Michelle T Ashworth, Jonathan Strosberg, et al.Cancer|August 18, 2016
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodiesAlain P Algazi, Katy K Tsai, Alexander N Shoushtari, et al.Cancer Immunology Research|August 30, 2019
Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma PatientsDouglas B Johnson, Kevin B Taylor, Justine V Cohen, et al.The Journal of Clinical Investigation|August 16, 2016
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanomaAdil I Daud, Kimberly Loo, Mariela L Pauli, et al.Cell|April 9, 2019
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4<sup>+</sup> T Cell ImmunityMikhail Binnewies, Adriana M Mujal, Joshua L Pollack, et al.JAMA Dermatology|August 10, 2017
Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the LiteratureAlexandra M Haugh, Ching-Ni Njauw, Jeffrey A Bubley, et al.Nature Medicine|October 6, 2020
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trialAlain P Algazi, Megan Othus, Adil I Daud, et al.BJC Reports|November 8, 2024
Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of responseZoe Quandt, Saya Jacob, Muhammad Zaki Hidayatullah Fadlullah, et al.Pageof 8